Novartis holds annual healthcare entrepreneur competition
- Details
- Category: Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp (BioCamp). Over the course of three days, students will gain first-hand experience of starting a biotechnology company as well as developing and launching an innovative healthcare product.
Nexavar® (sorafenib) granted priority review for differentiated thyroid cancer in the U.S.
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the Supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets, for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash.
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
Novartis first company accredited with global CEO Cancer Gold Standard
- Details
- Category: Novartis
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company's efforts to provide support to Novartis associates in the prevention, diagnosis and treatment of cancer.
GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies. The fund's first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases.
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
- Details
- Category: Novartis
Novartis has announced that results of a global Phase III study showed that Afinitor® (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or intolerance to sorafenib[1].
More Pharma News ...
- AstraZeneca PLC second quarter and half year results 2013
- GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
- Pfizer to create separate, internal, global Innovative and Value businesses
- Bristol-Myers Squibb and Samsung BioLogics announce biopharmaceutical manufacturing relationship
- Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing
- Bristol-Myers Squibb reports second quarter 2013 financial results
- AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application